Form 4: Xenon CEO Ian Mortimer Receives Substantial Equity Grants

Xenon Pharmaceuticals Inc. President and CEO, Ian Mortimer, was granted 350,000 stock options and 65,000 restricted share units on January 9, 2026.

Summary

• Ian Mortimer, President & CEO and Director of Xenon Pharmaceuticals Inc. (XENE), reported new equity grants.
• The grants include 350,000 share options with an exercise price of $42.15 per share.
• These options were granted on January 9, 2026, and are set to expire on January 8, 2036.
• The share options will vest 25% on January 9, 2027, with the remaining 75% vesting thereafter over the course of the next three years, in equal amounts, on the last day of each month.
• Additionally, 65,000 Restricted Share Units (RSUs) were granted.
• Each restricted share unit represents a contingent right to receive one Common Share.
• The RSUs will vest 25% on each of the first four anniversaries of the grant date, beginning on January 9, 2027.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: Slightly positive due to the strong alignment of management and shareholder interests through significant equity grants, balanced by the potential for future dilution.

Positives

• The significant equity grants align the interests of President & CEO Ian Mortimer with those of shareholders, incentivizing long-term performance and value creation.
• The multi-year vesting schedules for both the stock options and Restricted Share Units (RSUs) promote long-term retention and commitment from key management.
• The explicit mention of a Rule 10b5-1(c) plan indicates a pre-arranged transaction, which is a positive for corporate governance as it reduces concerns about opportunistic insider trading.

Negatives

• The issuance of new equity awards, particularly stock options and RSUs, can lead to potential future dilution for existing shareholders when these awards are exercised or vested.

Risks

• Potential future dilution of existing shareholders if the options are exercised and RSUs vest, increasing the total number of outstanding shares.
• The value of these awards is directly tied to the company's stock performance, meaning if the stock price declines, the intended incentive effect for management may diminish.

Industry Context

Executive equity compensation, including a combination of stock options and restricted share units, is a standard practice in the biotechnology and pharmaceutical industry. These grants are typically structured with multi-year vesting schedules to attract, retain, and incentivize key leadership, aligning management's long-term interests with shareholder value creation in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The structure of these equity grants, which includes both stock options and restricted share units with multi-year vesting schedules, is consistent with common executive compensation practices observed across the pharmaceutical and biotechnology sectors.
• The use of a Rule 10b5-1 plan for these transactions is a standard corporate governance practice, demonstrating pre-planned trading and mitigating concerns of opportunistic insider trading, similar to practices at companies like Pfizer or Amgen.
• The exercise price of $42.15 for the options, typically set at the closing price on the grant date, aligns with the industry standard for 'at-the-money' option grants to executives.

Stakeholder Impact

• **Shareholders:** Potential for future dilution from the exercise of options and vesting of RSUs, but also benefit from increased management incentive for long-term stock performance and value creation.
• **Employees:** May signal confidence in the company's future and potentially set a precedent for other executive compensation structures within the organization.
• **Management (Ian Mortimer):** Receives significant personal financial incentive directly tied to the company's stock price performance over the next decade, fostering a strong alignment with corporate objectives.

Next Steps

• Continued vesting of 75% of the share options monthly over three years following January 9, 2027.
• Continued vesting of 25% of the restricted share units on each of the next three anniversaries of the grant date (January 9, 2028, 2029, and 2030).

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Ian Mortimer, SEC Form 4, Insider Transaction, Stock Options, Restricted Share Units, Equity Grant, Executive Compensation, Rule 10b5-1